海南产白花蛇舌草对原发性肝癌"癌毒"的影响

Hainan Herba Hedyotis Effect on 'Cancerous Toxin' of Primary Liver Cancer

摘要:

目的: 从临床症状、生活质量、肝功能及肿瘤微环境等方面探讨长期服用海南产白花蛇舌草对原发性肝癌(PLC)"癌毒"的抑制作用.方法: 75例PLC患者根据不同的治疗方式分为复方斑蝥胶囊组(对照组)34例和白花蛇舌草组(观察组)41例.对照组服用复方斑蝥胶囊,3粒/次,2次/d.观察组采用海南产白花蛇舌草鲜草250~500 g或干草60~120 g ·d^-1,水煎煮2次,分3~4次内服.两组均随访6个月或直至死亡.对主要症状、体征及生活质量(KPS)进行评分;采用CT或核磁共振成像(MRI)评价治疗前后实体瘤大小;计算两组生存率;检测治疗前后丙氨酸氨基转移酶(ALT),天门冬氨酸氨基转移酶(AST),γ-谷胺酰转肽酶及其同工酶(γ-GT)和甲胎蛋白(AFP)水平;检测治疗前后血管内皮生长因子(VEGF)和转化生长因子-β(TGF-β)水平.结果: 经有序资料卡方分析,观察组实体瘤疗效优于对照组(P<0.05);观察组在治疗后3,6个月,主要症状、体征评分均低于对照组,KPS评分均高于对照组(P<0.05);治疗后观察组ALT,AST,γ-GT水平均低于对照组(P<0.05,P<0.01);对照组在6个月内生存率为58.8%,低于观察组的80.5%(P<0.05);治疗后观察组VEGF,TGF-β和AFP低于对照组(P<0.01).结论: 长期服用海南产白花蛇舌草能减轻PLC癌毒所致各种临床症状、减轻癌毒对肝细胞的损害,缩小癌肿块,改善PLC患者的炎性微环境,抑制肿瘤血管生成,从而有利于提高患者的生存率.

Abstract:

Objective:To discuss the inhibition of cancerous toxin of preinvasive liver cancer (PLC) by longer-term using of Herba Hedyotis from clinical symptoms, quality of life, liver function and tumor microenvironment. Method: Seventy-five patients with PLC were randomly divided into the control group (34 cases) and the Herba Hedyotis(observation) group (41 cases) by random number table. Patients in the control group received Fufang Banmao capsules, 3 capsules twice daily. Patients in the observation group received Hainan Herba Hedyotis 250-500 g fresh herb, or 60-120 g dry herb 3 or 4 times daily after decocting for two times. Patients in both groups were followed until death or for at least 6 months Cardinal symptom and signs, quality of life (Karnofsky Performance Status, KPS) were graded. Tumor respone was evaluated on the basis of solid tumor size by CT or MRI before and after treatment. Survival rates in both groups were calculated. Levels of alanine aminotransferase (ALT), aspartate amino transferase (AST), γ-glutamyltranspeptidase (γ-GT) and its isozyme, and alpha fetoprotein (AFP) were detected. Levels of vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGF-β) were also detected. Result: The solid tumor curative effect in observation group was superior to that in control group (P<0.05) from ordinal data card analysis. The main signs and symptoms scores in observation group were lower than those in control group, while the KPS score in observation group were higher than that in control group at the third and sixth month after treatment (P<0.05). Levels of ALT, AST and γ-GT in observation group were inferior to those in control group (P<0.05 or P<0.01). The survival rate of 58.8% in control group was lower than 80.5% in observation group during the 6 months (P<0.05). After treatment, the VEGF, TGF-βand AFP in observation group were inferior to those in control group (P<0.01). Conclusion: Long-term using of Herba Hedyotis can relieve a variety of clinical symptoms, reduce the damage to liver cells, shrink tumor mass, improve inflammatory microenvironment and inhibit tumor angiogenesis of PLC patients. Thus, the benefits in improving patients' survival rates are obtained.